EUVIMEDEUVIMED entdecken
Open Access · CC BY 2.0

TGFβ1, SMAD and β-catenin in pulmonary arteries of smokers, patients with small airway disease and COPD: potential drivers of EndMT

Prem Bhattarai, Wenying Lu, Ashutosh Hardikar, Archana Vijay Gaikwad, Surajit Dey, Affan Mahmood Shahzad, Stephen Myers, Andrew Williams, Darren Sutherland, Gurpreet Kaur Singhera, Tillie-Louise Hackett, Mathew S Eapen iD und 1 weitere

Clinical Science · 04.09.2024 · 138 (17) · 1055-1070

DOI: 10.1042/cs20240721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, online erschienen am 28.08.2024. Verfasst von Prem Bhattarai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, beta Catenin, Transforming Growth Factor beta1, Pulmonary Artery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: Clifford Craig Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported pulmonary arterial remodelling and active endothelial-to-mesenchymal transition (EndMT) in smokers and patients with early chronic obstructive pulmonary disease (COPD). In the present study, we aimed to evaluate the role of different drivers of EndMT. Immunohistochemical staining for EndMT drivers, TGF-β1, pSMAD-2/3, SMAD-7, and β-catenin, was performed on lung resections from 46 subjects. Twelve were non-smoker-controls (NC), six normal lung function smokers (NLFS), nine patients with small-airway diseases (SAD), nine mild-moderate COPD-current smokers (COPD-CS) and ten COPD-ex-smokers (COPD-ES). Histopathological measurements were done using Image ProPlus softwarev7.0. We observed lower levels of total TGF-β1 (P<0.05) in all smoking groups than in the non-smoking control (NC). Across arterial sizes, smoking groups exhibited significantly higher (P<0.05) total and individual layer pSMAD-2/3 and SMAD-7 than in the NC group. The ratio of SAMD-7 to pSMAD-2/3 was higher in COPD patients compared with NC. Total β-catenin expression was significantly higher in smoking groups across arterial sizes (P<0.05), except for COPD-ES and NLFS groups in small and medium arteries, respectively. Increased total β-catenin was positively correlated with total S100A4 in small and medium arteries (r = 0.35, 0.50; P=0.02, 0.01, respectively), with Vimentin in medium arteries (r = 0.42, P=0.07), and with arterial thickness of medium and large arteries (r = 0.34, 0.41, P=0.02, 0.01, respectively). This is the first study uncovering active endothelial SMAD pathway independent of TGF-β1 in smokers, SAD, and COPD patients. Increased expression of β-catenin indicates its potential interaction with SMAD pathway, warranting further research to identify the deviation of this classical pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic Obstructivebeta CateninTransforming Growth Factor beta1Pulmonary ArterySmokingHumansMaleFemaleMiddle AgedAgedSmad2 ProteinEpithelial-Mesenchymal TransitionSmad7 ProteinSmokersCase-Control StudiesSmad3 ProteinAdultEndothelial-Mesenchymal Transition

Stichwörter der Autor:innen

Endothelial to mesenchymal transitionSmall airway diseaseSmokingTGF-β1/SMAD pathwayVascular remodellingchronic obstructive pulmonary disease

Substanzen

beta CateninTransforming Growth Factor beta1TGFB1 protein, humanCTNNB1 protein, humanSmad2 ProteinSMAD7 protein, humanSMAD2 protein, humanSmad7 ProteinSmad3 ProteinSMAD3 protein, human

Autor:innen und Institutionen

  • Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania 7248, Australia.
  • Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania 7000, Australia.
  • Department of Cardiothoracic Surgery, The Royal Adelaide Hospital, Adelaide South Australia, 5000 Australia.
  • Department of Anaesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.
  • Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.

ORCID-Profile: Mathew S Eapen

Förderung

  • Clifford Craig Foundation

Zitieren

APA

Bhattarai, P., Lu, W., Hardikar, A., Gaikwad, A. V., Dey, S., Shahzad, A. M., Myers, S., Williams, A., Sutherland, D., Singhera, G. K., Hackett, T. L., Eapen, M. S., & Sohal, S. S. (2024). TGFβ1, SMAD and β-catenin in pulmonary arteries of smokers, patients with small airway disease and COPD: potential drivers of EndMT. Clinical Science, 138(17), 1055-1070. https://doi.org/10.1042/cs20240721

Vancouver

Bhattarai P, Lu W, Hardikar A, Gaikwad AV, Dey S, Shahzad AM, et al. TGFβ1, SMAD and β-catenin in pulmonary arteries of smokers, patients with small airway disease and COPD: potential drivers of EndMT. Clinical Science. 2024;138(17):1055-1070. doi:10.1042/cs20240721

BibTeX
@article{Bhattarai2024,
  author = {Bhattarai, Prem and Lu, Wenying and Hardikar, Ashutosh and Gaikwad, Archana Vijay and Dey, Surajit and Shahzad, Affan Mahmood and Myers, Stephen and Williams, Andrew and Sutherland, Darren and Singhera, Gurpreet Kaur and Hackett, Tillie-Louise and Eapen, Mathew S and Sohal, Sukhwinder Singh},
  title = {TGFβ1, SMAD and β-catenin in pulmonary arteries of smokers, patients with small airway disease and COPD: potential drivers of EndMT},
  journal = {Clinical Science},
  year = {2024},
  volume = {138},
  number = {17},
  pages = {1055--1070},
  doi = {10.1042/cs20240721}
}
Kostenlos starten →